Skip to main content
Can-Fite BioPharma Ltd. logo

Can-Fite BioPharma Ltd. — Investor Relations & Filings

Ticker · CANF ISIN · IL0010944739 LEI · 549300ZLRH6GSBOHFZ59 TA Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2026-03-30 Regulatory Filings
Country IL Israel
Listing TA CANF

About Can-Fite BioPharma Ltd.

https://www.canfite.com/

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company with integrated drug discovery and development capabilities. The company specializes in creating orally bioavailable small-molecule drugs. Its proprietary platform technology is centered on the A3 adenosine receptor (A3AR), a therapeutic target highly expressed in cancer and inflammatory cells but minimally in normal cells. Can-Fite's compounds bind to A3AR to initiate anti-cancer and anti-inflammatory effects by modulating cellular signal transduction pathways. The company's advanced pipeline features proprietary drug candidates in Phase II and Phase III clinical development for treating oncology, inflammatory, liver, and metabolic diseases. A lead drug, Namodenoson, is in a pivotal Phase III study for advanced liver cancer.

Recent filings

Filing Released Lang Actions
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Regulatory Filings Classification · 1% confidence The document is a Form 6-K "Report of Foreign Private Issuer" filed with the U.S. SEC, containing a press release as Exhibit 99.1 and not a standalone financial report (10-K, IR), management discussion (MDA), earnings release (ER), etc. It therefore falls under the general “Regulatory Filings” fallback category.
2026-03-30 English
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Report Publication Announcement Classification · 1% confidence The document is a regulatory bulletin filed with the Israel Securities Authority/Tel Aviv Stock Exchange under Regulation 5, noting that a report (Form 6-K style) “is attached.” It does not contain the report itself, but simply announces its publication/attachment. This matches our definition of a Report Publication Announcement.
2026-03-30 English
6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
Foreign Filer Report
2026-03-30 English
20-F FOR 2025
Regulatory Filings
2026-03-26 Hebrew (modern)
20-F FOR 2025
Report Publication Announcement Classification · 1% confidence The document is a short TASE/ISA periodic report notice stating “Attached hereto is a report on 20-F” and provides a PDF link, without including the substantive 20-F content itself. It merely announces the publication of the 20-F annual report rather than containing the report body. Under the “menu vs meal” rule, this is an announcement of a report publication, fitting the Report Publication Announcement (RPA) category.
2026-03-26 English
2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Earnings Release Classification · 1% confidence The document is a Form 6-K filing by a foreign private issuer, furnishing Exhibit 99.1, which is a press release titled “Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress.” It provides a summary of the company’s full-year 2025 financial results (revenues, R&D expenses, net loss, cash position) and key clinical updates — matching the definition of an Earnings Release (initial announcement of periodical financial results). FY 2025
2026-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.